

Ref: 71/SE/LC/2024-25

Date: 12/11/2024

To,

**Head, Listing Compliance Department  
BSE Limited**

Phiroze Jeejeebhoy Towers Dalal Street,  
Mumbai - 400 001.

**Scrip Code: 544122**

**Head, Listing Compliance Department  
National Stock Exchange of India Limited**

Exchange Plaza, Plot No. C/1. G Block,  
Bandra -Kurla Complex, Bandra (East),  
Mumbai- 400051

**Scrip Symbol: ENTERO**

Dear Sir/Madam,

**Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. ('LODR')**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the '**SEBI Listing Regulations**'), we wish to inform you that the Company has entered into a binding Memorandum of Understanding for acquiring 100% stake in M/s. Shree Enterprises, partnership firm, through the Company or any one of its subsidiary Company, subject to satisfactory completion of due diligences and execution of definitive agreements and fulfilment of conditions therein, if any.

The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13<sup>th</sup> July, 2023 in respect of the entities proposed to be acquired, are given in **Annexure A** respectively, annexed hereto.

You are requested to take the same on record.

For **Entero Healthcare Solutions Limited**

Jayant Prakash

**General Counsel, Company Secretary & Compliance Officer**

(Mem: F6742)

### Annexure- A

The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13<sup>th</sup> July, 2023 are as under:

Sr. No.	Particulars	Details
a	Name of the target entity, details in brief such as size, turnover etc.	<p>M/s. Shree Enterprises , a partnership firm, having its office at TC25/2970(2) &amp; 25/2970 (3) Malloor Road , Vanchiyor, Thiruvananthapuram-695035</p> <p>Shree Enterprises is engaged in the business of wholesale distribution of pharmaceuticals and other allied products.</p> <p>The turnover of Shree Enterprises for the year 2023-2024 is INR 443.78 Mn.</p>
b.	whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm s length”	<p>Yes, the acquisition shall fall within related party transaction as directors of Subsidiary Company are partners in target entity.</p> <p>No, the promoter or promoter group of the Company does not have any interest in the entity being acquired.</p> <p>The transaction is at arm’s length basis.</p>
c.	Industry to which the entity being acquired belongs	Shree Enterprises operates in same line of business activity i.e business of distribution of pharmaceuticals, surgical and other healthcare and allied products.
d.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The business of Shree Enterprises is in line of the business of the Company i.e. wholesale distribution of pharmaceutical and other allied products and the acquisition of business of Shree Enterprises by the Company shall enable the Company to generate additional business and revenue on consolidated basis.

e.	brief details of any governmental or regulatory approvals required for the acquisition;	Not applicable.
f.	indicative time period for completion of the acquisition;	The acquisition shall be completed by January 31, 2025.
G.	consideration whether cash consideration or share swap or any other form and details of the same	The acquisition of Shree Enterprises will be through cash consideration.
h.	cost of acquisition and/or the price at which the shares are acquired;	The Company shall pay an amount upto INR 231.12 Mn (includes net assets and target based milestone achievement consideration) for the acquisition of the business of Shree Enterprises, subject to completion of due diligence.
i	percentage of shareholding / control acquired and / or number of shares acquired;	100% Stake acquisition through business transfer
j	brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<p>Shree Enterprises is engaged in the business of wholesale distribution of pharmaceutical and other allied products.</p> <p>The turnover of Shree Enterprises financial year 2021-2022 is INR 436.52 Mn, for financial year 2022-23 is INR 459.17 Mn and for financial year 2023-24 is INR 443.78 Mn.</p> <p>Shree Enterprises conducts its business only in India.</p>